ParkinsonCanadaV1, PascalFrancis, Curation, bibRecord, 000246

Peptidase activities of the 20/26S proteasome and a novel protease in human brain

Identifieur interne : 000246 ( PascalFrancis/Curation ); précédent : 000245; suivant : 000247

Peptidase activities of the 20/26S proteasome and a novel protease in human brain

Auteurs : Sophie Vigouroux [France] ; Yoshiaki Furukawa [Canada] ; Luc Farout [France] ; Stephen J. Kish [Canada] ; Marièle Briand [France] ; Yves Briand [France]

Source :

Journal of neurochemistry [ 0022-3042 ] ; 2003.

RBID : Pascal:03-0245854

Descripteurs français

Pascal (Inist)
- Peptidases, Multicatalytic endopeptidase complex, Omptin, Ubiquitine, Expression génique, Activité enzymatique, Démence Alzheimer, Parkinson maladie, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Alzheimer disease, Enzymatic activity, Gene expression, Human, Multicatalytic endopeptidase complex, Omptin, Parkinson disease, Peptidases, Ubiquitin.

Abstract

Many neurodegenerative diseases are characterized by ubiquitin-positive protein aggregates or inclusion bodies. Ubiquitin-conjugated proteins are degraded by the 20/26S proteasome, and reduced proteasome peptidase activities in brain homogenates have been reported in pathologic lesions of Parkinson's and Alzheimer's diseases. However, it is unknown whether crude extracts of human brain contain other proteases having peptidase activities. We found a novel protease of molecular weight of approximately 105 kDa in normal human brain, which exhibited trypsin-like (T-L) and chymotrypsin-like (ChT-L) activities (corresponding to 52% and 21% of the total activities in crude extracts) but not peptidyl glutamyl peptide hydrolase activity. Both T-L and ChT-L activities of this protease were partially inhibited by proteasome inhibitors (MG132, lactacystin) and, in contrast to those of the proteasome, also by sodium dodecyl sulfate. A simple method to obtain a brain fraction specific to the 20/26S proteasome was developed. Our human brain data suggest that T-L and ChT-L activity levels of the proteasome reported previously may include those of the 105 kDa protease, an enzyme of as yet unknown biological significance, and that it is necessary to separate the proteasome from this protease to evaluate the actual status of the ubiquitin-proteasome system in neurodegenerative disorders.

A01	`01`	`1`		`@0 0022-3042`
A02	`01`			`@0 JONRA9`
A03		`1`		`@0 J. neurochem.`
A05				`@2 84`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Peptidase activities of the 20/26S proteasome and a novel protease in human brain`
A11	`01`	`1`		`@1 VIGOUROUX (Sophie)`
A11	`02`	`1`		`@1 FURUKAWA (Yoshiaki)`
A11	`03`	`1`		`@1 FAROUT (Luc)`
A11	`04`	`1`		`@1 KISH (Stephen J.)`
A11	`05`	`1`		`@1 BRIAND (Marièle)`
A11	`06`	`1`		`@1 BRIAND (Yves)`
A14	`01`			`@1 Laboratoire de Biochimie Appliquée - UA INRA 995, Université Blaise Pascal @2 Aubière @3 FRA @Z 1 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division @2 Toronto, Ontario @3 CAN @Z 2 aut.`
A14	`03`			`@1 Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health-Clarke Division @2 Toronto, Ontario @3 CAN @Z 4 aut.`
A20				`@1 392-396`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 4037 @5 354000103724240180`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 13 ref.`
A47	`01`	`1`		`@0 03-0245854`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of neurochemistry`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Many neurodegenerative diseases are characterized by ubiquitin-positive protein aggregates or inclusion bodies. Ubiquitin-conjugated proteins are degraded by the 20/26S proteasome, and reduced proteasome peptidase activities in brain homogenates have been reported in pathologic lesions of Parkinson's and Alzheimer's diseases. However, it is unknown whether crude extracts of human brain contain other proteases having peptidase activities. We found a novel protease of molecular weight of approximately 105 kDa in normal human brain, which exhibited trypsin-like (T-L) and chymotrypsin-like (ChT-L) activities (corresponding to 52% and 21% of the total activities in crude extracts) but not peptidyl glutamyl peptide hydrolase activity. Both T-L and ChT-L activities of this protease were partially inhibited by proteasome inhibitors (MG132, lactacystin) and, in contrast to those of the proteasome, also by sodium dodecyl sulfate. A simple method to obtain a brain fraction specific to the 20/26S proteasome was developed. Our human brain data suggest that T-L and ChT-L activity levels of the proteasome reported previously may include those of the 105 kDa protease, an enzyme of as yet unknown biological significance, and that it is necessary to separate the proteasome from this protease to evaluate the actual status of the ubiquitin-proteasome system in neurodegenerative disorders.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Peptidases @2 FE @5 01`
C03	`01`	`X`	`ENG`	`@0 Peptidases @2 FE @5 01`
C03	`01`	`X`	`SPA`	`@0 Peptidases @2 FE @5 01`
C03	`02`	`X`	`FRE`	`@0 Multicatalytic endopeptidase complex @2 FE @5 02`
C03	`02`	`X`	`ENG`	`@0 Multicatalytic endopeptidase complex @2 FE @5 02`
C03	`02`	`X`	`SPA`	`@0 Multicatalytic endopeptidase complex @2 FE @5 02`
C03	`03`	`X`	`FRE`	`@0 Omptin @2 FE @5 03`
C03	`03`	`X`	`ENG`	`@0 Omptin @2 FE @5 03`
C03	`03`	`X`	`SPA`	`@0 Omptin @2 FE @5 03`
C03	`04`	`X`	`FRE`	`@0 Ubiquitine @5 04`
C03	`04`	`X`	`ENG`	`@0 Ubiquitin @5 04`
C03	`04`	`X`	`SPA`	`@0 Ubiquitina @5 04`
C03	`05`	`X`	`FRE`	`@0 Expression génique @5 05`
C03	`05`	`X`	`ENG`	`@0 Gene expression @5 05`
C03	`05`	`X`	`SPA`	`@0 Expresión genética @5 05`
C03	`06`	`X`	`FRE`	`@0 Activité enzymatique @5 07`
C03	`06`	`X`	`ENG`	`@0 Enzymatic activity @5 07`
C03	`06`	`X`	`SPA`	`@0 Actividad enzimática @5 07`
C03	`07`	`X`	`FRE`	`@0 Démence Alzheimer @5 09`
C03	`07`	`X`	`ENG`	`@0 Alzheimer disease @5 09`
C03	`07`	`X`	`SPA`	`@0 Demencia Alzheimer @5 09`
C03	`08`	`X`	`FRE`	`@0 Parkinson maladie @5 12`
C03	`08`	`X`	`ENG`	`@0 Parkinson disease @5 12`
C03	`08`	`X`	`SPA`	`@0 Parkinson enfermedad @5 12`
C03	`09`	`X`	`FRE`	`@0 Homme @5 54`
C03	`09`	`X`	`ENG`	`@0 Human @5 54`
C03	`09`	`X`	`SPA`	`@0 Hombre @5 54`
C07	`01`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Enzyme`
C07	`02`	`X`	`ENG`	`@0 Enzyme`
C07	`02`	`X`	`SPA`	`@0 Enzima`
C07	`03`	`X`	`FRE`	`@0 Serine endopeptidases @2 FE`
C07	`03`	`X`	`ENG`	`@0 Serine endopeptidases @2 FE`
C07	`03`	`X`	`SPA`	`@0 Serine endopeptidases @2 FE`
C07	`04`	`X`	`FRE`	`@0 Encéphale pathologie @5 20`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 20`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 20`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central @5 21`
C07	`05`	`X`	`ENG`	`@0 Central nervous system @5 21`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso central @5 21`
C07	`06`	`X`	`FRE`	`@0 Système nerveux pathologie @5 22`
C07	`06`	`X`	`ENG`	`@0 Nervous system diseases @5 22`
C07	`06`	`X`	`SPA`	`@0 Sistema nervioso patología @5 22`
C07	`07`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 23`
C07	`07`	`X`	`ENG`	`@0 Central nervous system disease @5 23`
C07	`07`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 23`
C07	`08`	`X`	`FRE`	`@0 Maladie dégénérative @5 24`
C07	`08`	`X`	`ENG`	`@0 Degenerative disease @5 24`
C07	`08`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 24`
C07	`09`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 25`
C07	`09`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 25`
C07	`09`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 25`
N21				`@1 153`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A77

Links to Exploration step

Pascal:03-0245854

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Peptidase activities of the 20/26S proteasome and a novel protease in human brain</title>
<author><name sortKey="Vigouroux, Sophie" sort="Vigouroux, Sophie" uniqKey="Vigouroux S" first="Sophie" last="Vigouroux">Sophie Vigouroux</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Biochimie Appliquée - UA INRA 995, Université Blaise Pascal</s1>
<s2>Aubière</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Farout, Luc" sort="Farout, Luc" uniqKey="Farout L" first="Luc" last="Farout">Luc Farout</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Biochimie Appliquée - UA INRA 995, Université Blaise Pascal</s1>
<s2>Aubière</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health-Clarke Division</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Briand, Mariele" sort="Briand, Mariele" uniqKey="Briand M" first="Marièle" last="Briand">Marièle Briand</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Biochimie Appliquée - UA INRA 995, Université Blaise Pascal</s1>
<s2>Aubière</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Briand, Yves" sort="Briand, Yves" uniqKey="Briand Y" first="Yves" last="Briand">Yves Briand</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Biochimie Appliquée - UA INRA 995, Université Blaise Pascal</s1>
<s2>Aubière</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0245854</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0245854 INIST</idno>
<idno type="RBID">Pascal:03-0245854</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A77</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000246</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Peptidase activities of the 20/26S proteasome and a novel protease in human brain</title>
<author><name sortKey="Vigouroux, Sophie" sort="Vigouroux, Sophie" uniqKey="Vigouroux S" first="Sophie" last="Vigouroux">Sophie Vigouroux</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Biochimie Appliquée - UA INRA 995, Université Blaise Pascal</s1>
<s2>Aubière</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Farout, Luc" sort="Farout, Luc" uniqKey="Farout L" first="Luc" last="Farout">Luc Farout</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Biochimie Appliquée - UA INRA 995, Université Blaise Pascal</s1>
<s2>Aubière</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health-Clarke Division</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Briand, Mariele" sort="Briand, Mariele" uniqKey="Briand M" first="Marièle" last="Briand">Marièle Briand</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Biochimie Appliquée - UA INRA 995, Université Blaise Pascal</s1>
<s2>Aubière</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Briand, Yves" sort="Briand, Yves" uniqKey="Briand Y" first="Yves" last="Briand">Yves Briand</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Biochimie Appliquée - UA INRA 995, Université Blaise Pascal</s1>
<s2>Aubière</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of neurochemistry</title>
<title level="j" type="abbreviated">J. neurochem.</title>
<idno type="ISSN">0022-3042</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of neurochemistry</title>
<title level="j" type="abbreviated">J. neurochem.</title>
<idno type="ISSN">0022-3042</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer disease</term>
<term>Enzymatic activity</term>
<term>Gene expression</term>
<term>Human</term>
<term>Multicatalytic endopeptidase complex</term>
<term>Omptin</term>
<term>Parkinson disease</term>
<term>Peptidases</term>
<term>Ubiquitin</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Peptidases</term>
<term>Multicatalytic endopeptidase complex</term>
<term>Omptin</term>
<term>Ubiquitine</term>
<term>Expression génique</term>
<term>Activité enzymatique</term>
<term>Démence Alzheimer</term>
<term>Parkinson maladie</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Many neurodegenerative diseases are characterized by ubiquitin-positive protein aggregates or inclusion bodies. Ubiquitin-conjugated proteins are degraded by the 20/26S proteasome, and reduced proteasome peptidase activities in brain homogenates have been reported in pathologic lesions of Parkinson's and Alzheimer's diseases. However, it is unknown whether crude extracts of human brain contain other proteases having peptidase activities. We found a novel protease of molecular weight of approximately 105 kDa in normal human brain, which exhibited trypsin-like (T-L) and chymotrypsin-like (ChT-L) activities (corresponding to 52% and 21% of the total activities in crude extracts) but not peptidyl glutamyl peptide hydrolase activity. Both T-L and ChT-L activities of this protease were partially inhibited by proteasome inhibitors (MG132, lactacystin) and, in contrast to those of the proteasome, also by sodium dodecyl sulfate. A simple method to obtain a brain fraction specific to the 20/26S proteasome was developed. Our human brain data suggest that T-L and ChT-L activity levels of the proteasome reported previously may include those of the 105 kDa protease, an enzyme of as yet unknown biological significance, and that it is necessary to separate the proteasome from this protease to evaluate the actual status of the ubiquitin-proteasome system in neurodegenerative disorders.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-3042</s0>
</fA01>
<fA02 i1="01"><s0>JONRA9</s0>
</fA02>
<fA03 i2="1"><s0>J. neurochem.</s0>
</fA03>
<fA05><s2>84</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Peptidase activities of the 20/26S proteasome and a novel protease in human brain</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VIGOUROUX (Sophie)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FURUKAWA (Yoshiaki)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>FAROUT (Luc)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KISH (Stephen J.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BRIAND (Marièle)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BRIAND (Yves)</s1>
</fA11>
<fA14 i1="01"><s1>Laboratoire de Biochimie Appliquée - UA INRA 995, Université Blaise Pascal</s1>
<s2>Aubière</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health-Clarke Division</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>392-396</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>4037</s2>
<s5>354000103724240180</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>13 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0245854</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of neurochemistry</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Many neurodegenerative diseases are characterized by ubiquitin-positive protein aggregates or inclusion bodies. Ubiquitin-conjugated proteins are degraded by the 20/26S proteasome, and reduced proteasome peptidase activities in brain homogenates have been reported in pathologic lesions of Parkinson's and Alzheimer's diseases. However, it is unknown whether crude extracts of human brain contain other proteases having peptidase activities. We found a novel protease of molecular weight of approximately 105 kDa in normal human brain, which exhibited trypsin-like (T-L) and chymotrypsin-like (ChT-L) activities (corresponding to 52% and 21% of the total activities in crude extracts) but not peptidyl glutamyl peptide hydrolase activity. Both T-L and ChT-L activities of this protease were partially inhibited by proteasome inhibitors (MG132, lactacystin) and, in contrast to those of the proteasome, also by sodium dodecyl sulfate. A simple method to obtain a brain fraction specific to the 20/26S proteasome was developed. Our human brain data suggest that T-L and ChT-L activity levels of the proteasome reported previously may include those of the 105 kDa protease, an enzyme of as yet unknown biological significance, and that it is necessary to separate the proteasome from this protease to evaluate the actual status of the ubiquitin-proteasome system in neurodegenerative disorders.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Multicatalytic endopeptidase complex</s0>
<s2>FE</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Multicatalytic endopeptidase complex</s0>
<s2>FE</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Multicatalytic endopeptidase complex</s0>
<s2>FE</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Omptin</s0>
<s2>FE</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Omptin</s0>
<s2>FE</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Omptin</s0>
<s2>FE</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Ubiquitine</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Ubiquitin</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Ubiquitina</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Expression génique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Gene expression</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Expresión genética</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Activité enzymatique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Enzymatic activity</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Actividad enzimática</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Démence Alzheimer</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Alzheimer disease</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Demencia Alzheimer</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>54</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>54</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>54</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Serine endopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Serine endopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Serine endopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>20</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>20</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>20</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>21</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>21</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>21</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>22</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>22</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>22</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>23</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>23</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>23</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>24</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>24</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>24</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>25</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>25</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>25</s5>
</fC07>
<fN21><s1>153</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000246 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000246 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:03-0245854
   |texte=   Peptidase activities of the 20/26S proteasome and a novel protease in human brain
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Peptidase activities of the 20/26S proteasome and a novel protease in human brain

Peptidase activities of the 20/26S proteasome and a novel protease in human brain

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri